文献速递前列腺癌

术前PSMA PET淋巴结阳性与根治性前列腺切除术后生化复发及治疗生存期缩短相关

Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
PubMed 文献 · J Urol · 2021-02-04

该单中心回顾性研究纳入230例中高危前列腺癌患者,术前接受68Ga-PSMA-11 PET后行根治性前列腺切除及盆腔淋巴结清扫。PSMA PET对pN1的敏感度48.5%、特异度95.7%;中位随访30.2个月,PSMA PET淋巴结阳性且病理pN1者生化复发无生存期和治疗无生存期最差。

要点

  • 术前PSMA PET淋巴结阳性提示根治术后早期生化复发和需辅助/挽救治疗。
  • PSMA PET对pN1敏感度48.5%、特异度95.7%,阴性者仍有病理淋巴结转移可能。
  • PSMA PET结果可用于患者咨询、强化随访及新辅助/辅助治疗规划。

核心结论

  • 术前PSMA PET显示淋巴结阳性的前列腺癌患者,即便行彻底盆腔淋巴结清扫,仍预期早期生化复发和辅助/挽救治疗。

研究设计与样本

  • 2013至2017年单中心单臂回顾性观察研究,纳入64例中危和166例高危共230例前列腺癌患者。
  • 患者术前接受68Ga-PSMA-11 PET,随后行根治性前列腺切除和盆腔淋巴结清扫。
  • 采用单变量和多变量Cox比例风险模型及单变量Kaplan-Meier分析,显著性阈值p<0.05。

主要发现

  • PSMA PET对pN1病的总体敏感度48.5%、特异度95.7%、阳性预测值82.1%、阴性预测值82.2%。
  • 中位随访30.2个月,50.4%(116例)患者发生生化复发,46.5%(107例)接受辅助或挽救治疗。
  • PSMA PET淋巴结阳性且病理pN1者生化复发无生存期和治疗无生存期最差,中位生化复发无生存期1.7个月,中位治疗无生存期2.6个月。
  • 病理pN1但PSMA PET淋巴结阴性者中位生化复发无生存期7.5个月、中位治疗无生存期8.9个月。
  • 病理和PSMA PET均无淋巴结转移证据者中位生化复发无生存期和治疗无生存期均>36个月。

临床怎么用

  • 术前PSMA PET淋巴结阳性结果可用于患者咨询,告知早期复发和辅助/挽救治疗风险。
  • 对PSMA PET淋巴结阳性患者可考虑更严格的随访及新辅助/辅助治疗规划。

局限性

  • 研究为单中心、单臂、回顾性观察设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to address the impact of preoperative prostate specific membrane antigen (PSMA) positron emission tomography (PET) findings prior to radical prostatectomy and pelvic lymph node dissection on biochemical recurrence and time to adjuvant or salvage treatment. MATERIALS AND METHODS: Between 2013 and 2017, 64 intermediate and 166 high risk (230) prostate cancer patients received 68Ga-PSMA-11 PET followed by radical prostatectomy and pelvic lymph node dissection. Biochemical recurrence-free and therapy-free survivalwere determined. For all time-to-event analyses, univariable and multivariable Cox proportional hazards models and univariable Kaplan-Meier analyses were applied, with a significance threshold of p <0.05. RESULTS: The overall sensitivity, specificity, positive predictive value and negative predictive value of PSMA PET for pN1 disease was 48.5%, 95.7%, 82.1% and 82.2%, respectively. Median followup was 30.2 months. Biochemical recurrence occurred in 50.4% (116) of patients and adjuvant or salvage treatment was performed in 46.5% (107). Worst biochemical recurrence-free and therapy-free survival was observed in pN1 patients who also exhibited PSMA PET positive lymph node, followed by pN1 patients without PSMA PET positive lymph node and patients without evidence of lymph node metastasis on histology and PSMA PET (median biochemical recurrence-free survival 1.7 vs. 7.5 vs. >36 months, median therapy-free survival 2.6 vs. 8.9 vs. >36 months). CONCLUSIONS: Patients with positive lymph node on PSMA PET prior to radical prostatectomy have to expect early biochemical recurrence and adjuvant/salvage therapy, despite thorough pelvic lymph node dissection. Therefore, results from PSMA PET can be used for patients' consultation and more stringent followup as well as for planning of neoadjuvant/adjuvant therapy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Amiel T, Würnschimmel C, Heck M, et al. Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study. J Urol. 2021. PMID: 33535796. doi:10.1097/JU.0000000000001596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。